January 23, 2023 03:45 AM ESTUpdated 04:15 AM
People
Bioregnum

What’s with Bris­tol My­ers’ R&D job cuts in New Jer­sey? They’re not say­ing much

It’s not un­usu­al these days to hear chat­ter about R&D lay­offs, with biotechs of all stripes cut­ting back and carv­ing out longer run­ways through cost …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times